Pharvaris (NASDAQ:PHVS) President Sells 15,000 Shares

Pharvaris N.V. (NASDAQ:PHVS) President Peng Lu sold 15,000 shares of the company’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $40.13, for a total value of $601,950.00. Following the completion of the sale, the president directly owned 65,179 shares in the company, valued at $2,615,633.27. This trade represents a 18.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Peng Lu also recently made the following trade(s):

• On Tuesday, September 8th, Peng Lu sold 15,000 shares of Pharvaris stock. The stock was sold at an average price of $40.68, for a total value of $610,200.00.
• On Thursday, June 18th, Peng Lu sold 300 shares of Pharvaris stock. The stock was sold at an average price of $34.00, for a total transaction of $10,200.00.

Pharvaris Stock Performance

NASDAQ PHVS traded down $0.61 during trading hours on Tuesday, reaching $38.25. The company’s stock had a trading volume of 1,020,979 shares, compared to its average volume of 398,337. The company’s 50-day moving average is $35.20 and its two-hundred day moving average is $31.49. Pharvaris N.V. has a fifty-two week low of $20.65 and a fifty-two week high of $43.25. The stock has a market cap of $2.50 billion, a PE ratio of -12.54 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Equities analysts expect that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PHVS has been the topic of a number of analyst reports. New Street Research set a $60.00 target price on Pharvaris in a report on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. Wedbush lifted their price objective on Pharvaris from $42.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Wall Street Zen downgraded shares of Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Finally, Oppenheimer restated an “outperform” rating and issued a $75.00 target price on shares of Pharvaris in a report on Tuesday, September 8th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pharvaris currently has an average rating of “Moderate Buy” and an average target price of $59.87.

Key Stories Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris’ shares have gained about 10% over the past month after Phase 3 results showed that the extended-release formulation of deucrictibant reduced hereditary angioedema attacks by 83%. The data support the company’s plans to pursue regulatory submissions in 2027 and strengthen the outlook for its lead drug candidate. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst price-target expectations have improved. The reported consensus target was raised approximately 20% to $59.77, while RBC recently increased its target to $62 and maintained an outperform rating. The broader analyst view remains favorable, with a consensus “Moderate Buy” rating and an average target near $60. Pharvaris NV consensus price target raised 20.08% to $59.77
• Neutral Sentiment: Institutional ownership trends have been supportive, with investors including BlackRock and Alyeska Investment Group building positions. This may provide additional demand, although the purchases reflect earlier reporting periods rather than a new catalyst.
• Negative Sentiment: Several insiders recently sold shares. Director Anne Lesage sold 30,000 shares for approximately $1.15 million, while CEO Berndt Modig sold 2,291 shares for about $90,000 and President Peng Lu sold 15,000 shares for roughly $602,000. Lu’s transaction was made to cover tax withholding on vested equity awards, which reduces its negative signal, but the volume of insider selling could still weigh on sentiment. Insider Selling: Pharvaris Insider Sells 30,000 Shares

Institutional Trading of Pharvaris

Hedge funds have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new stake in Pharvaris in the 2nd quarter valued at about $41,000. CoreCap Advisors LLC acquired a new position in Pharvaris in the second quarter valued at $93,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in Pharvaris during the fourth quarter valued at about $139,000. Public Employees Retirement System of Ohio purchased a new stake in Pharvaris during the second quarter valued at about $196,000. Finally, Algert Global LLC acquired a new stake in Pharvaris during the second quarter worth about $238,000.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.